Category Archives: Cell Therapy

New York, March 07, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Gene Therapy Market Size, Share & Trends Analysis Report By Indication, By Vector Type, By Region And Segment Forecasts, 2020 - 2027" - https://www.reportlinker.com/p05445418/?utm_source=GNW

The global gene therapy market size is expected to reach USD 6.6 billion by 2027, at a CAGR of 16.6% over the forecast period. The approval of early CAR-T-based gene therapy products has created lucrative avenues in product approvals over expanded indications. Clinical trials for T-cell therapies each year has risen exponentially in the recent past. Constant developments in CAR-T cell therapy are recognized as one of the key driving factors for market growth.

Although gene therapy has primarily been used for cancer treatment, it increasingly finds application in the treatment of various rare and incurable diseases. Approval of products for non-cancer applications, such as approval of Bluebird Bio's Zynteglo in June 2019 for ?-thalassemia, indicates the shift in preferences of companies toward other untapped segments.

Gene therapies involve complex molecules and hence manufacturing these molecules is a challenge for developers, particularly in with regard to specialized manufacturing facilities and highly skilled technical personnel. This has created lucrative avenues for contract service providers operating in the space.

Further key findings from the study suggest: Since viral vectors are the most conventional method for the delivery of genes, several operating players have designed their gene therapy programs based on viral vectors In 2019, the lentivirus and retrovirus generated significant revenue owing to the approval of lentivirus-based Kymriah and retrovirus-based Yescarta in 2017 by the U.S. FDA Among various indications, a majority of the revenue share is generated by various forms of cancer. This is attributed to the presence of approved products for cancer forms such as acute lymphoblastic leukemia (ALL), large B-cell lymphoma, and melanoma North America dominated the global gene therapy market in 2019 as U.S. is the largest market for clinical trials related to gene therapy, since around 60.0% of all clinical trials in the world are carried out in the country. Moreover, FDA approval of Kymriah and Yescarta in U.S. in 2017 and Kymriah in Canada in 2018 has resulted in huge investments by sponsors and government agencies in North America Key market players include Bluebird Bio, Novartis AG, UniQure NV, Gilead Sciences, Spark Therapeutics LLC, and Celgene Corporation These players are engaged in signing licensing, commercialization, and development agreements with other market participants to expand their business operations in cell and gene therapy domain. For instance, Novartis Pharmaceuticals received commercialization rights for Spark Therapeutics' Luxturna for selling the product outside U.S.Read the full report: https://www.reportlinker.com/p05445418/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more here:
Gene Therapy Market Size, Share & Trends Analysis Report By Indication, By Vector Type, By Region And Segment Forecasts, 2020 - 2027 - Benzinga

Cancer Stem Cell Therapy Market research report has been published by A2Z Market Research to give desired insights to drive the growth of businesses. The report has been intelligently framed with the process of gathering and calculating numerical data regarding services and products. The report is inclusive of the prominent industry drivers and provides an accurate analysis of the key growth trends and market outlook in the years to come in addition to the competitive hierarchy of this sphere.

Get Sample copy of this Report @: http://www.a2zmarketresearch.com/sample?reportId=194432

Some of the Top Companies covered in this Report includes: AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems.

The global Cancer Stem Cell Therapy market is analyzed in terms of its competitive landscape. For this, the report encapsulates data on each of the key players in the market according to their current company profile, gross margins, sale price, sales revenue, sales volume, product specifications along with pictures, and the latest contact information. The reports conclusion leads into the overall scope of the global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the global Cancer Stem Cell Therapy market in the near future.

The report summarized the high revenue that has been generated across locations like, North America, Japan, Europe, Asia, and India along with the facts and figures of Cancer Stem Cell Therapy market. It focuses on the major points, which are necessary to make positive impacts on the market policies, international transactions, speculation, and supply demand in the global market.

Global Cancer Stem Cell Therapy Market Detail Segmentation:

Segmentation by Type:

Segmentation by Application:

For More Information, [emailprotected]: http://www.a2zmarketresearch.com/enquiry?reportId=194432

Impressive insights of Global Cancer Stem Cell Therapy Market Research report:

Table of Contents

Global Cancer Stem Cell Therapy Market Research Report 2020 2026

Chapter 1 Cancer Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Cancer Stem Cell Therapy Market Forecast

Buy Complete Report Only @ 2800 USD: http://www.a2zmarketresearch.com/buy?reportId=194432

If you have any special requirements, please let us know and we will offer you the report as you want.

See the original post here:
Increasing Demand of Cancer Stem Cell Therapy Market by 2020-2026 with Top Key Players like #VALUE! - News Times

Second highest year for global financings in regenerative medicine, with nearly $10 billion raised globally

Washington, DC, March 05, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM) today announced the release of its 2019 Annual Report and Sector Year in Review, highlighting the organizations key priorities and initiatives, as well as offering an in-depth look at trends and metrics for the cell therapy, gene therapy and tissue engineering sector.

ARM, which celebrated its 10th anniversary in 2019, is the premier international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector. In its 2019 annual report, the organization provides an update on its work with industry, national and international regulatory agencies, public and private payers, patient organizations and other stakeholders to create a positive environment for the development of and access to these innovative therapies.

Using data sourced from ARMs data partner Informa, the report also provides analysis on industry-specific statistics and trends from nearly 1,000 leading cell therapy, gene therapy, tissue engineering, and other regenerative medicine companies worldwide. Key features of the report include total financings for the sector, partnerships and other deals, clinical trial information, anticipated near-term product approvals and regulatory filings, and expert commentary from industry representatives in the US and Europe.

Key findings from the 2019 annual report include:

ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trial numbers, and clinical data events.

The report is available to download onlinehere, with interactive data and downloadable infographics availablehere. Past reports, issued quarterly and annually, are availablehere.

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 350 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visithttp://www.alliancerm.org.

Kaitlyn Donaldson Dupont803-727-8346kdonaldson@alliancerm.org

Follow this link:
The Alliance for Regenerative Medicine Releases 2019 Annual Report and Sector Year in Review - Yahoo Finance

The Global Cell Therapy and Tissue Engineering Market research report 2020-2026 is an elementary and professional detailing of the essential elements driving the Cell Therapy and Tissue Engineering market growth rate and the revenue statistic of the specific industry. Several comprehensive elements including Cell Therapy and Tissue Engineering market share, supply chain, Cell Therapy and Tissue Engineering market trends, revenue graph, Cell Therapy and Tissue Engineering market size and application spectrum are widely administrated in this study. The world Cell Therapy and Tissue Engineering market report is said to an accurate competitive overview of the business-driven outlook elaborating on expansion tactics adopted by major competitors of the Cell Therapy and Tissue Engineering industry.

Get Free Sample Report Of Cell Therapy and Tissue Engineering Market Report: https://marketsresearch.biz/report/global-cell-therapy-tissue-engineering-market-402204#request-sample

As per the latest study, the global Cell Therapy and Tissue Engineering industry is expected to gather vital estimations while registering a lucrative annual growth rate during the predicted time period. The research document also showcases most crucial information related to the complete assessment that market retains and an in-depth analysis of the Cell Therapy and Tissue Engineering industry along with the availability of several growth opportunities.

In the recently published report, our experts have widely introduced a large set of essential parameters such as development policies as well as plans, cost structures, and a brief manufacturing processes. Moreover, the report studies cost, supply and demand figures, gross margins, import or export consumption, revenue and price. It also focuses on the world Cell Therapy and Tissue Engineering market players offering a list of significant details such as product image and its specification, company profiles, revenue, Cell Therapy and Tissue Engineering market share, capacity, Cell Therapy and Tissue Engineering market size, contact into production and so on.

Checkout Inquiry For Buying or Customization of Report: https://marketsresearch.biz/report/global-cell-therapy-tissue-engineering-market-402204#inquiry-for-buying

Global Cell Therapy and Tissue Engineering market report offers in-depth information about the major market players

Betalin TherapeuticsBioCardia, IncBioReliance CorporationBiosolution Co.Brainstorm Cell Therapeutics, IncMaxCyte, IncMedigene AGMEDIPOST CO.Mesoblast LimitedMiromatrix Medical, Inc.MolMed S.p.AMustang Bio, IncNantKwest, Inc.Neuralstem, IncNexImmune, Inc.Nohla Therapeutics, IncReNeuron Group plcRichter-Helm BioLogics GmbH & Co. KGRoosterBio, IncRoslinCTRubius Therapeutics, Inc.Sangamo Therapeutics, IncVoyager Therapeutics, IncWaisman BiomanufacturingWindMIL Therapeutics, Inc.Wuxi App Tec, Inc.ReNeuron Group plcRichter-Helm BioLogics GmbH & Co. KGRoosterBio, IncRoslinCT

Global Cell Therapy and Tissue Engineering Market Segmentation By Type

Cell TherapyTissue Engineering

Global Cell Therapy and Tissue Engineering Market Segmentation By Application

Cell DefectsGenetic DiseasesNeurodegenerative DiseasesTissue MalignanciesOthers

Checkout Free Report Sample of Cell Therapy and Tissue Engineering Market Report 2020-2026: https://marketsresearch.biz/report/global-cell-therapy-tissue-engineering-market-402204#request-sample

The global Cell Therapy and Tissue Engineering market development trends and industrial channels are also investigated in this report. It covers an in-depth analysis as well as feasibility of newly investment projects. Along with the bunch of tables and figures the recent study report offer significant statistics on the actual state of the worldwide Cell Therapy and Tissue Engineering industry and recommended source of guidance and direction for numerous enterprises and interested players in the Cell Therapy and Tissue Engineering market.

The Global Cell Therapy and Tissue Engineering market report 2020 is considered as an expert guide and detailed research on the worlds key regional industry conditions of the Cell Therapy and Tissue Engineering market that completely focusing on the primitive regions as well as countries of the globe. The study report also describes the fundamental information about the Cell Therapy and Tissue Engineering market such as application, industry outlook, definition, Cell Therapy and Tissue Engineering market chain structure, policy analysis, classification and more. Insightful estimations for the worldwide Cell Therapy and Tissue Engineering market for the upcoming few years have also been involved in the report.

See the article here:
2020-2026 Cell Therapy and Tissue Engineering Global Market By Betalin Therapeutics, BioCardia, Inc, BioReliance Corporation, Biosolution Co. -...

Most development-stage biopharmaceutical companies pin their hopes on a single clinical hypothesis evaluated with a handful of drug candidates at best. Fate Therapeutics(NASDAQ:FATE) is not most early stage companies.

The cellular therapy pioneer is developing 13 unique pipeline programs. That may give the impression that Fate Therapeutics is throwing everything at the wall and seeing what sticks, but a closer look shows there's been a rational build-out of the pipeline. That doesn't necessarily mean all of the hypotheses will work -- development-stage biopharmas are inherently risky investments -- but if the lead clinical programs report promising data in 2020 from the next wave of major trials, investors might begin to see the value of the company's vision.

Here's why this pharma stock is my top buy in March.

Image source: Getty Images.

Fate Therapeutics has staked its future on the general idea that first-generation immunotherapies leave much room for improvement. It's not wrong. The successful development of chimeric antigen receptor (CAR) T cells put cellular therapy on the map a few years ago, but there are inherent limitations to their production and use.

Take Yescarta as an example. In the second half of 2017, it became the second CAR-T drug to earn approval from the U.S. Food and Drug Administration (FDA). It's a personalized medicine used to treat certain cancers of white blood cells. To make a dose, immune cells are harvested from a patient, isolated, genetically engineered to attack the patient's cancer, multiplied in the lab, and then administered back into the patient.

The immunotherapy is highly effective. In a large post-approval study involving 533 individuals, Yescarta achieved an overall response rate of 84% and a complete response rate of 66%. That means 84% of individuals responded to treatment and 66% of individuals had no evidence of disease after six months. The study proved why Gilead Sciences was wise to acquire Kite Pharma, which developed Yescarta and pioneered CAR-T therapies.

But first-generation immunotherapies such as Yescarta have limitations. Using donor- or patient-derived cells increases the complexity of treatment, which increases costs and the potential for errors. Manufacturing a dose of a patient-derived CAR-T therapy can take two to three weeks and cost $425,000. Hospitals administering CAR-T therapies can charge as much as $1.5 million to ensure they aren't losing money while adhering to stringent protocols.

CAR-T therapies can also cause severe side effects including cytokine release syndrome (CRS) and neurotoxicities (Yescarta comes with a boxed warning for these side effects). They can only be dosed once. And engineering them with first-generation gene editing tools such as CRISPR/Cas9 has been found to be error-prone. Fate Therapeutics thinks there's a better way.

Image source: Getty Images.

Fate Therapeutics is developing cellular therapies that address most of the concerns of first-generation CAR-T therapies.

Rather than rely on cells derived from each individual patient, the company engineers cells from a master clonal cell line. That allows for an off-the-shelf drug product that can be easily reproduced, confidently characterized for quality control, and efficiently manufactured in batches. The company estimates its manufacturing cost is less than $2,500 per dose. Individuals can also receive treatment in an outpatient setting and avoid racking up massive hospital bills.

The development-stage biopharma is also relying mostly on natural killer (NK) cells, which have several advantages compared to CAR-T cells.NK cells shouldn't be accompanied by severe side effects such as CRS or neurotoxicities, can rally the rest of an individual's immune system to attack tumors, and can be dosed multiple times to extend the duration of response. It's also possible to combine NK cells with other drugs, especially monoclonal antibodies, which could provide unique synergies to improve patient outcomes.

Fate Therapeutics has also tapped Inscripta's novel CRISPR gene-editing tool, which uses a novel cutting enzyme that has been shown to be more efficient than Cas9. That's important for ensuring all cells used for a drug product are homogeneous, rather than a distribution of cells with varying genetic profiles and levels of activity.

On paper, the company's approach stacks up favorably against a general first-generation cellular therapy.

Metric

First-Generation Cellular Therapy

Fate Therapeutics

Starting material

Cells derived from patient

Cells derived from master clonal cell line (nine of 13 clinical programs)

Manufacturing process

Complex process required to make a single dose

Manufactured in batches (many doses from one production run)

Manufacturing time and cost

2-3 weeks and $450,000

Available off the shelf and less than $2,500

Engineering tools

Error-prone first-generation CRISPR/Cas9 tools

Next-generation CRISPR tool using MAD7 enzyme is more efficient than Cas9 (first drug candidate could begin trials in 2020)

Cell type and dosing

CAR-T cells that can be dosed only once

Mostly NK cells that can be dosed multiple times (eight of 13 clinical programs)

Side effects

CRS and neurotoxicities

No cases of CRS reported in early studies of NK cells

Data source: Fate Therapeutics.

The benefits on paper are nice, but investors will be more concerned with how the approach stacks up in the real world -- and 2020 might be the year they get an answer.

Fate Therapeutics is developing cellular therapies against a range of solid tumor cancers and blood cancers. The company made six presentations at the American Society of Hematology (ASH) annual meeting in December, which provided investors with the first real glimpse of the pipeline's potential.

The takeaways were mostly positive and certainly raised the level of intrigue on Wall Street, as evidenced by a rising stock price. Fate Therapeutics notched several industry firsts (such as with FT500, which became the first off-the-shelf derived NK cell therapy to begin a clinical trial) while setting the stage for more important data readouts in 2020.

Drug Candidate, Cell Type

Indication

Last Update

FT516 (monotherapy), NK cell

Acute myeloid leukemia (AML)

First patient received one cycle of three once-weekly doses, had no evidence of disease in bone marrow at Day 42.

FT516 (combination therapy), NK cell + monoclonal antibody

B-cell lymphoma

First patient received one cycle of three once-weekly doses, no data reported.

FT500 (monotherapy or combination), NK cell or NK cell + checkpoint inhibitor

Advanced solid tumors in individuals who failed prior checkpoint inhibitor therapy

12 patients total, six of 11 evaluable patients achieved stable disease after first cycle, no cases of CRS or neurotoxicity in 62 total doses.

Data source: Fate Therapeutics Press releases.

Fate Therapeutics also plans to initiate new studies in 2020. A combination therapy comprising a FT596 (an NK cell drug candidate) and rituximab (a monoclonal antibody) is expected to begin a phase 1 study in lymphoma in early 2020. Meanwhile, the company expects to submit investigational new drug (IND) applications for its first off-the-shelf CAR-T cell product, FT819, and first CRISPR-edited product, FT538, in the second quarter of this year.

Fate Therapeutics began the year with $261 million in cash, which means investors and Wall Street analysts will be solely focused on clinical results and the continued buildout of the pipeline in 2020.

While all development-stage biopharma stocks are inherently risky, the number of shots on goal insulates investors from a single failure. In fact, each drug candidate is genetically engineered against unique molecular targets, or used in specific combinations, which means any single clinical failure can't be extrapolated across the entire pipeline.

Fate Therapeutics still needs to generate clinical results demonstrating its next-generation approach to cellular therapy can lead to robust clinical benefits for patients, but Wall Street and deep-pocketed industry leaders might coalesce around the development-stage company if early and mid-stage studies continue to impress. That could make its current $2.3 billion market valuation a bargain for investors with a long-term mindset -- and with an appetite for above-average risk.

See original here:
Here's My Top Stock to Buy in March - Motley Fool

CAPE CANAVERAL, Fla. SpaceX is preparing for its fifth launch of the year: a resupply mission to the International Space Station (ISS). The mission, which is scheduled to launch Friday (March 6) at 11:50 p.m. EST (0450 GMT on March 7), will bring a bevy of science material to the astronauts living and working in the orbiting laboratory.

This flight, dubbed CRS-20, marks the 20th and final mission for SpaceX under the company's first commercial cargo resupply services contract with NASA. Perched atop a Falcon 9 rocket will sit a cargo Dragon capsule filled with more than 4,300 lbs. (1,950 kilograms) of supplies, including more than 2,100 lbs. (950 kg) of science equipment.

The scientific cargo will support a host of experiments across Expeditions 62 and 63, focusing on a range of topics, from biological sciences (growing human heart cells in space), to water conservation methods, to particle-foam manufacturing and the addition of a new research platform on the ISS.

You can watch SpaceX's Dragon launch livehere on Space.com, courtesy of SpaceX, beginning at about 11:30 p.m. EST (0430 GMT), courtesy of NASA TV. You can alsowatch the launch directly from SpaceX here, beginning at 11:35 p.m. EST (0435 GMT).

Video: What's flying to the space station on SpaceX's CRS-20 mission?Related: SpaceX Dragon cargo ship launching tonight. How to watch live.

In its never-ending quest to create the best athletic shoe, Adidas has turned its sights to the International Space Station. The sportswear company has developed a performance midsole an additional shoe layer between the insole (next to your feet) and the sole (what touches the ground) that will enhance comfort.

To create its midsole, Adidas uses a process called particle foam molding, in which thousands of small pellets are blasted into a mold so they fuse together. To streamline the process and create the best shoe it can, Adidas is going to try this process in microgravity. The experiment, dubbed Adidas BOOST (Boost Orbital Operations on Spheroid Tessellation), will look at how the particles fuse together in space.

By removing gravity from the process, the team can take a closer look at individual pellet motion and location. The results of this investigation could show that the space station is a good platform for testing out new manufacturing methods and could lead to more-efficient means of packing and cushioning materials.

Related: Adidas launching new sneakers inspired by historic NASA spacesuits

Delta Faucet Co., a manufacturer of shower heads and other bathroom hardware, is launching a payload on CRS-20 that will seek to better understand how water droplets form. The company will use that knowledge to build a better shower head that lines up with Delta's ultimate goal: creating the sensation of increased pressure while using less water.

Conserving water is incredibly important, but one of the biggest drawbacks is that eco-friendly, low-flow shower heads do not perform as well as their less environmentally friendly counterparts. Users complain that the water pressure feels so low it's difficult to rinse off properly, which can result in longer showers and, ultimately, more water usage.

To help mitigate this issue, Delta has created a unique shower head, called the H2Okinetic, that controls the size and the speed of the water droplets with the help of an oscillating chip. That chip creates a better shower experience by breaking up the water flow into bigger droplets and shooting them out faster, giving the illusion of more water.

Related: Showering in space: Astronaut home video shows off 'hygiene corner'

"Water is a precious commodity," Garry Marty, principal engineer at Delta Faucet, said during a prelaunch briefing on Thursday (March 5). "We are trying to create a shower head to keep our customers happy while using less water."

He went on to explain that once the water leaves the pipes, it essentially doesn't have any pressure. What you're feeling are the droplets. With this new shower head, Delta Faucet is able to control the size and speed on each drop, revolutionizing the way a shower device delivers a shower.

"Lower-flow showers aren't really great to be under," Marty said. "But the more we understand, the more we can improve."

Marty added that, someday, humanity will be living on the moon or Mars and will need a way to take a shower. The lessons learned from this research go beyond conserving water and user experience, he said; it has implications for the space industry as well. But for now, the bigger concern is to better understand the fundamentals of water droplet formation.

Heart disease is the No. 1 cause of death in the U.S. A team of researchers from Emory University in Atlanta, led by Chunhui Xu, are sending an experiment up to the space station to explore how effectively stem cells can be turned into heart muscle cells.

The data collected could lead to new therapies and even speed up the development of new drugs that can better treat heart disease.

The microgravity environment found on the space station is known to have a profound effect on cell growth. Through this research, the team aims to understand the impact microgravity has on cardiac precursors (cardiac cells created from stem cells) and how effectively they produce cardiac muscle cells, called cardiomyocytes.

Related: Heart cells beat differently in microgravity, may benefit astronauts

Ground-based research shows that when cells are grown under simulated microgravity conditions, the production rate of cardiomyocytes is greater than if they were grown under the effects of gravity. By sending the experiment to the space station, Xu and her team will be able to determine if their results are accurate.

"Our goal is to help make stem cell-based therapy more readily available," Xu said during the briefing. "If successful, the demand for it will be tremendous, because heart disease is the No. 1 killer in America."

In order to have a successful therapy, Xu said that the team will need to produce a large number of high-quality cardiomyocytes. To do that, the researchers need to first understand the mechanisms behind cell transformation.

Bartolomeo is a new research platform that will be installed on the exterior of the space station. Placed outside the European Columbus module, this science balcony will host as many as 12 research experiments at one time.

Built by Airbus, the platform will enable researchers to conduct more experiments on the station's exterior. During a prelaunch briefing, NASA and Airbus explained that Bartolomeos potential uses include Earth observation, robotics, materials science and astrophysics.

"All of your [research] dreams can come true with Bartolomeo," said Andreas Schuette, program manager of Bartolomeo at Airbus.

And parking spots on the washing machine-sized platform are all-inclusive, which means that researchers can pay one price to launch, install, operate and even return to Earth. By working directly with agencies like NASA, ESA, and SpaceX, Airbus is able to offer a cost-effective means of conducting research on the space station.

The company is also working with the United Nations in an effort to entice those who wouldn't otherwise be able to afford to send payloads into space, Schuette told Space.com. The duo have teamed up with the United Nations Office for Outer Space (UNOOSA) to make that happen. (The agency works to make space more accessible.)

If all goes as scheduled, the Dragon will arrive at the International Space Station on Monday (March 9) at approximately 6 a.m. EDT (1000 GMT). From there, NASA astronauts Jessica Meir and Drew Morgan will use the station's Canadarm2 robotic arm to capture and attach the spacecraft, before beginning the unloading process.

Follow Amy Thompson on Twitter @astrogingersnap. Follow us on Twitter @Spacedotcom or Facebook.

Read more here:
SpaceX Dragon to launch heart cell experiment and more to space station tonight - Space.com

Global Cell Therapy Technologies Market research reports contain data that can help companies deal with this issue easily and provide detailed qualitative and quantitative details related to market elements of interest to the organization. Similarly, it incorporates the required business profiles of some major manufacturers.

This report starts with a market overview and provides an analysis of market definitions and drivers, constraints, and key trends. The following sections include regional trading activity, end-users, transaction types, and Global Cell Therapy Technologies Market analysis. In this section, we evaluate the market based on various factors covering current scenarios and future prospects. The report also provides regional data for regional and international companies.

Request Sample Copy of this Report @ https://www.healthcareintelligencemarkets.com/request_sample.php?id=135881

This market research report analyzes the growth prospects for the key players operating in this Global

Cell Therapy Technologies Market including Top Key Players:

Insulet Corporation, GlucoMe Medtronic ,F. Hoffmann-La Roche, Abbott, Dexcom, LifeScan, Jiangsu Delfu medical device

This is anticipated to drive the Global Cell Therapy Technologies Market over the forecast period 2020-2027. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Cell Therapy Technologies Market are currently adopting new technological trends in the market.

Market by Key Regions:

The research report also addresses innovations, new developments, marketing strategies, branding technologies, and products from key participants in the Global Cell Therapy Technologies Market. For the future in this report. The report offers opportunities and limitations to hit future Global Cell Therapy Technologies Market participants. This report makes it easy for consumers to gain insight into the growth of Global Cell Therapy Technologies Market products in the market.

Get Reasonable Discount up to 40% on this Premium Report @ https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=135881

Reasons for Buying this Report:

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Cell Therapy Technologies Market. The feasibility of the new report is also measured in this research report.

If You Have Any Query, Ask Our Experts: @ https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=135881

Table of Content:

About Us:

At HealthCare Intelligence Markets, we supply market intelligence reports in the domain of personalized drugs & diagnostics after going through a rigorous research process. The healthcare industry is constantly evolving as trends are getting replaced at a rapid pace.

These new trends along with the changing demands of patients and healthcare organizations are collectively contributing to the development of the global healthcare industry.

The reports made by us are updated on a regular basis to cover the latest developments in the industry. Our workforce is comprised of seasoned market research professionals who can also provide customized reports as per the exclusive needs.

HealthCare helps clients decode the future to be more successful and innovative.

Contact US:

90, State Office Center,90,

State Street Suite 700,

Albany, NY 12207

+44-753-712-1342

Email:[emailprotected]

Web:www.healthcareintelligencemarkets.com

Read more from the original source:
Best Informative Report on Cell Therapy Technologies Market Is Expected To Generate Huge Profits by 2020 2027 with Top Key Players- Johnson &...

5. CAR T-Cell Therapy Improves Quality of Life for Adult Patients with LymphomaA study offers evidence that chimeric antigen receptor T-cell therapy may not only extend patients survival, but also improve their quality of life after treatment. Read more.

4. FDA Grants Fast Track Designation to Therapy for Recurrent or Metastatic Adenoid Cystic CarcinomaAL101 is a potent, selective, injectable small molecule gamma secretase inhibitor and was granted Orphan Drug designation in May 2019 for the treatment of recurrent or metastatic adenoid cystic carcinoma. Read more.

3. Prioritizing Patient Access to Specialty Drugs: The Best of Both WorldsSpecialty pharmacies can provide seamless support across specialty mail and retail channels. Read more.

2. Evidence: Vital but Seldom Used Consistently by PayersPeer-reviewed research conducted by the National Pharmaceutical Council and the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center over the past 2 years sheds some light on whats behind the discrepancies in coverage decisions from one insurer to the next. Read more.

1. Gilead Sciences Buys Immuno-Oncology Company Forty Seven IncGilead has agreed to pay $95.50 per share in cash for Forty Seven Inc, adding the 5-year old biotechnology company to bolster its portfolio of oncology drugs. Read more.

See the original post here:
Gilead Acquisition of Forty Seven Inc Tops SPT Week in Review - Pharmacy Times

The success of approved stem cell therapies has caused a surge in interest of biopharma developers in this field; many innovator companies are currently progressing proprietary leads across different phases of clinical development, with cautious optimism

LONDON, March 4, 2020 /PRNewswire/ -- Roots Analysishas announced the addition of "Global Stem Cells Market: Focus on Clinical Therapies, 20202030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))" report to its list of offerings.

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years.

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link

Key Market Insights

Over 280 stem cell therapies are under development, most of which are allogeneic products

More than 50% of the pipeline candidates are in the mid to late phase trials (phase II and above), and allogenic therapies (majority of which are derived from the bone marrow) make up 65% of the pipeline.

70% of pipeline candidates are based on mesenchymal stem cells

It is worth highlighting that the abovementioned therapies are designed to treat musculoskeletal (22%), neurological (21%) and cardiovascular (15%) disorders. On the other hand, hematopoietic stem cell-based products are mostly being evaluated for the treatment of oncological disorders, primarily hematological malignancies.

Close to 85% stem cell therapy developers are based in North America and Asia-Pacific regions

Within these regions, the US, China, South Korea and Japan, have emerged as key R&D hubs for stem cell therapies. It is worth noting that majority of the initiatives in this domain are driven by small / mid-sized companies

Over 1,500 grants were awarded for stem cell research, since 2015

More than 45% of the total amount was awarded under the R01 mechanism (which supports research projects). The NCI, NHLBI, NICHD, NIDDK, NIGMS and OD emerged as key organizations that have offered financial support for time periods exceeding 25 years as well.

Outsourcing has become indispensable to R&D and manufacturing activity in this domain

Presently, more than 80 industry / non-industry players, based in different regions across the globe, claim to provide contract development and manufacturing services to cater to the unmet needs of therapy developers. Examples include (in alphabetical order) Bio Elpida, Cell and Gene Therapy Catapult, Cell Tech Pharmed, GenCure, KBI Biopharma, Lonza, MEDINET, Nikon CeLL innovation, Roslin Cell Therapies, WuXi Advanced Therapies and YposKesi.

North America and Asia-Pacific markets are anticipated to capture over 80% share by 2030

The stem cell therapies market is anticipated to witness an annualized growth rate of over 30% during the next decade. Interestingly, the market in China / broader Asia-Pacific region is anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom stem cell therapies are currently considered to be a promising alternatives for the treatment of a myriad of disease indications, with the potential to overcome challenges associated with conventional treatment options. The report includes detailed transcripts of discussions held with the following experts:

The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), stem cell therapy portfolio and an informed future outlook.

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.htmlor email sales@rootsanalysis.com

You may also be interested in the following titles:

Contact:Gaurav Chaudhary+1(415)800-3415+44(122)391-1091Gaurav.Chaudhary@rootsanalysis.com

Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg

Read the original:
With Over 280 Therapies Under Evaluation, the Stem Cell Therapy Market is Estimated to be Worth USD 8.5 Billion by 2030, Claims Roots Analysis - P&T...

Ori Biotech has partnered with software firm TrakCel to add supply chain monitoring technology to its cell and gene therapy manufacturing system.

The non-exclusive deal financial terms of which were not disclosed will allow cell and gene therapy developers and contract development and manufacturing organizations (CDMOs) that use the Ori platform to monitor manufacturing processes in real-time using Trakcels technologies.

The firms plan to develop suitable points of integration in order for a shared data platform to be available to partners.

Image: iStock/angelp

Ori co-founder and CSO Farlan Veraitch said, The integration of TrakCels advanced therapy supply chain tracking software with the Ori full-stack platform is another step forward enabling our customers to have full visibility throughout the supply chain.

This was echoed by Fiona Withey, co-founder and CEO, TrakCel.

She said, Closed system manufacturing is becoming progressively more important for the ongoing future of the cell and gene therapy sector, and we look forward to working with Ori to offer more integrated solutions to the wider industry.

Oris technology is an automated, closed cell process system composed of a scalable bioreactor and fluid handling platform.

The platform is designed to help developers reduce the time and cost involved in making autologous cell therapies according to CEO Jason C. Foster who spoke with Bioprocess Insider in January.

The deal with Trakcel comes after a busy period for Ori.

In early January firm completed a $9.4M (7M) Seed Round with backers including Amadeus Capital Partners, Delin Ventures and Kindred Capital. At the time Ori said it would use the proceeds to bring its manufacturing platform to market.

A few weeks later Ori announced it had partnered with Hitachi Chemical Advanced Therapeutics Solutions (HCATS), the contract development and manufacturing organization (CDMO) subsidiary of Hitachi Chemical Company.

The deal covered the development and commercialization of technology solutions specific to the cell and gene therapy industry.

Ori told us The first external tests of the Ori platform begin in March 2020 with our CDMO partner, HCATS, and our two therapeutics developer partners.

Read more: Ori: Partnerships key to bring down cell therapy COGS

Read the original post:
Ori biotech adds traceability to cell therapy platform - Bioprocess Insider - BioProcess Insider